Skip to main content

Sunlenca Side Effects

Generic name: lenacapavir

Medically reviewed by Drugs.com. Last updated on Oct 21, 2023.

Note: This document contains side effect information about lenacapavir. Some dosage forms listed on this page may not apply to the brand name Sunlenca.

Applies to lenacapavir: oral tablet. Other dosage forms:

Serious side effects of Sunlenca

Along with its needed effects, lenacapavir (the active ingredient contained in Sunlenca) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lenacapavir:

Incidence not known

For Healthcare Professionals

Applies to lenacapavir: oral tablet, subcutaneous solution.

Gastrointestinal

Common (1% to 10%): Nausea[Ref]

General

The most common adverse reactions reported in at least 3% patients were nausea and injection site reactions.[Ref]

Hepatic

Common (1% to 10%): Increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased direct bilirubin[Ref]

Local

Four percent patients experienced Grade 3 ISRs (erythema, pain, swelling)[Ref]

Very common (10% or more): Injection site reactions (65%) [include swelling (36%), pain (31%), erythema (31%), nodule (25%), induration (15%), pruritus (6%), extravasation (3%) discomfort (1%), mass (3%), hematoma (1%), edema (1%) and ulcer (1%)][Ref]

Metabolic

Common (1% to 10%): Glycosuria, hyperglycemia, proteinuria[Ref]

Musculoskeletal

Very common (10% or more): Increased creatinine (13%)[Ref]

References

1. Product Information. Sunlenca (lenacapavir). Gilead Sciences. 2022.

2. Product Information. Sunlenca (lenacapavir). Gilead Sciences Pty Ltd. 2023;SUNLENCA Product Inf.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.